WEST LAFAYETTE, Ind. – Kylin Therapeutics, Inc., a leading RNAi company, announced that it has raised a Series A-1 round of financing of approximately $1.2 million from private investors.

“This financing places Kylin in a strong financial position. We are delighted that our investors recognize the value of Kylin’s proprietary RNAi delivery technology, pRNA.” said J. Eric Davis, J.D., president and CEO of Kylin Therapeutics. “Kylin will use the proceeds of this offering to continue to advance and develop our ‘pRNAi’ technology,” added Mr. Davis.

About Kylin Therapeutics

Kylin Therapeutics, Inc., (www.kylintherapeutics.com) a biotechnology company, employs a revolutionary RNA nanoparticle technology platform called “pRNA” to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases. This visionary platform has enormous potential to meet the huge market opportunity for treating cancer and other diseases with RNA-based therapeutics. The unique capabilities of the platform have enabled Kylin to overcome the most significant challenges in the development of RNA-based therapies.

Kylin Therapeutics was founded in late 2006, based on technology developed by Dr. Peixuan Guo at Purdue University.